Fig. 6: ESR predicts the therapeutic efficacy of PROTACs in vivo.

a Schematic illustration of tumor inoculation and treatment protocol for 4T1 xenograft mice. b Tumor growth curves of mice with different treatments during 15-day monitoring (n = 5 mice per group). c Weights of tumors in different treatments over 15 days. High (10 mg/kg) versus PBS (0 mg/kg): ****P < 0.0001, two-tailed Student t-test analysis (Data are presented as mean value ± SD, n = 5 mice per group). d Body weight changes in different treatment groups over 15 days (Data are presented as mean value ± SD, n = 5 mice per group). e Image of tumors in different treatments over 15 days (n = 5 mice per group). f Fluorescence imaging of JQ1-NR signals in mice pretreated with different doses of JV8. (n = 5 mice per group). g The variation of JQ1-NR fluorescent signals at 4 h after probe injection (n = 5 mice per group). h The relative tumor volume of mice with different treatments during 15-day monitoring (Data are presented as mean value ± SD, n = 5 mice per group). i Plotting of the relative tumor volume changes at day 14 and the ΔFL changes. j Western blotting analysis of BRD4 levels in 4T1 tumor after varying treatments (n = 3 mice per group). k Quantification of (j) (Data are presented as mean value ± SD, n = 3 mice per group). l Correlations of the ΔFL changes, the relative BRD4 expression and the relative tumor volume changes at day 14 are shown in a radar chart. Pearson r was derived using a simple linear regression model. Source data are provided as a Source Data file. Figure 6a is created in https://BioRender.com.